STOCK TITAN

BeOne Medicines Ltd. (ONC) Stock News

ONC NASDAQ

Ticker history: BGNE became ONC (BeOne Medicines Ltd.) on . Earlier news and filings retain their original names and dates. View BGNE history.

BeOne Medicines Ltd. (ONC) generates a steady flow of oncology news that reflects its focus on hematology and solid tumors. As a Switzerland‑domiciled global oncology company with listings on NASDAQ, the Hong Kong Stock Exchange and the STAR Market in Shanghai, BeOne regularly issues updates on clinical data, regulatory milestones, financial performance and corporate developments.

Investors and healthcare professionals following ONC news will see frequent announcements related to B‑cell malignancies, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The company highlights new data for its BTK inhibitor BRUKINSA, including long‑term results from Phase 3 trials such as SEQUOIA and ALPINE, as well as patient‑reported outcomes and guideline updates. News also covers sonrotoclax, an investigational BCL2 inhibitor, with items on FDA Breakthrough Therapy Designation, Priority Review for relapsed or refractory MCL, and clinical results in CLL and other B‑cell cancers. Updates on BTK degrader BGB‑16673 from the CaDAnCe clinical program appear alongside these hematology releases.

On the solid tumor side, BeOne’s news includes Phase 3 trial results for ZIIHERA (zanidatamab) plus TEVIMBRA (tislelizumab) and chemotherapy in first‑line HER2‑positive gastroesophageal adenocarcinoma, as well as regulatory plans based on these data. Additional releases describe TEVIMBRA’s expanding indications and BGB‑B2033’s FDA Fast Track Designation in hepatocellular carcinoma. Financial news items provide quarterly revenue, product sales trends for BRUKINSA and TEVIMBRA, cash flow metrics and updated guidance, while corporate updates cover conference presentations, research milestones and agreements such as the IMDELLTRA royalty purchase arrangement with Royalty Pharma.

For users tracking ONC, this news stream offers insight into BeOne’s evolving hematology and solid tumor portfolios, its regulatory interactions in major markets and its stated goal of broadening patient access to cancer therapies. Bookmarking the ONC news page on Stock Titan allows readers to follow company press releases, clinical milestones and financial disclosures in one place.

Rhea-AI Summary

BeOne Medicines (ONC) announced an expanded partnership with CLL Society to support education and resources for patients and healthcare professionals.

Under the three-year Visionary Partnership, BeOne is expanding its support for CLL Society to $3 million. The initiatives focus on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Planned work includes education about biomarker testing before treatment, digital resources with AI-enabled search and personalization, and expert interviews and webinars. The programs are designed to help patients, care partners and healthcare providers find information and understand treatment options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary

BeOne Medicines (NASDAQ: ONC) raised its 2026 revenue outlook after reporting third-quarter revenue growth of 34% from the prior-year period. Revenue reached $1.9 billion, including $1.4 billion from BRUKINSA. GAAP operating income rose 157% to $418.675 million, while diluted earnings per American Depositary Share increased to $3.28 from $1.09. Free cash flow rose 34% to $473.532 million.

BeOne now expects 2026 revenue of $6.9 billion–$7.0 billion and GAAP operating income of $1.2 billion–$1.3 billion. Quarterly GAAP product gross margin improved to 88% from 86%, despite a $22 million impairment tied to discontinuing POBEVCY promotion. Tacabrutideg met its pivotal Phase 2 response endpoint in previously treated chronic lymphocytic leukemia. BeOne also secured Japanese approval for TEVIMBRA in first-line nasopharyngeal cancer and announced a collaboration and regional rights agreement with Revolution Medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
-
Rhea-AI Summary

BeOne Medicines (ONC) received FDA Priority Review for BRUKINSA plus rituximab to treat adults with previously untreated mantle cell lymphoma. The FDA accepted the supplemental application, supported by the randomized Phase 3 MANGROVE trial comparing the chemotherapy-free combination with bendamustine plus rituximab.

Among 510 patients, the combination reduced the risk of progression or death by 43% versus the comparator, meeting the primary endpoint of progression-free survival assessed by an independent review committee. No new safety signals were identified. Full results will be presented at the American Society of Hematology Annual Meeting on December 13, 2026.

A supplemental MCL application has also been submitted to the European Medicines Agency and accepted by China's Center for Drug Evaluation. BRUKINSA already has U.S. approval for adults with relapsed or refractory MCL.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
none
Rhea-AI Summary

BeOne Medicines (NASDAQ: ONC) will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026. Its fireside chat is scheduled for 9:30 a.m. GMT. A live webcast will be accessible through the investor section at https://ir.beonemedicines.com, with an archived webcast available on the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
-
Rhea-AI Summary

BeOne Medicines (ONC) presented early-stage liver and lung cancer trial results and a Phase 3 breast cancer study update at ESMO 2026. BGB-B2033 produced a 36.0% confirmed objective response rate, measuring tumor shrinkage, at its recommended Phase 3 dose in liver cancer. The estimated six-month confirmed response-duration rate was 74.1%. BeOne plans global registrational trials by the end of 2026.

In lung cancer, BGB-58067 achieved a 25.3% confirmed response rate among 75 evaluable patients with MTAP-deficient disease. Preliminary BG-C477 results showed a 56.0% confirmed response rate in patients with high CEA expression. Both programs are intended to advance toward late-stage development in 2027. Severe adverse events occurred in each program. The Phase 3 KANDELA-302 breast cancer trial began enrollment in May 2026, comparing BGB-43395 plus letrozole with selected CDK4/6 inhibitors plus letrozole.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
-
Rhea-AI Summary

BeOne Medicines (ONC) reported updated Phase 3 survival results for TEVIMBRA plus ZIIHERA and chemotherapy in first-line HER2-positive advanced gastroesophageal cancer. After 35.3 months of follow-up in HERIZON-GEA-01, median overall survival was 27.0 months with the combination versus 19.6 months with trastuzumab plus chemotherapy. Estimated survival at 36 months was 39.8% versus 22.9%.

ZIIHERA plus chemotherapy achieved median overall survival of 22.9 months, meeting the remaining primary endpoint versus trastuzumab plus chemotherapy. Adding TEVIMBRA to ZIIHERA plus chemotherapy was associated with longer survival but did not reach statistical significance in an underpowered analysis (P=0.0502). Both experimental regimens improved progression-free survival versus trastuzumab plus chemotherapy. No new safety signals emerged; diarrhea was the most common severe treatment-related adverse event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
Rhea-AI Summary

BeOne Medicines (ONC) will report its third quarter 2026 financial results on November 5, 2026, before financial markets open.

Management will host a live webcast at 8:00 a.m. ET following the results release. The webcast will be accessible through the company’s investor website, where an archived version will also be available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
earnings date
-
Rhea-AI Summary

BeOne Medicines (ONC) will present solid tumor pipeline and TEVIMBRA data at the ESMO Congress on October 23–27, 2026, in Madrid.

Presentations cover four investigational programs: Phase 1 liver cancer data for BGB-B2033, first-in-human data for BG-C477 and BGB-58067, and the ongoing Phase 3 KANDELA-302 breast cancer trial of BGB-43395. Seven TEVIMBRA abstracts include the second interim analysis of HERIZON-GEA-01, evaluating ZIIHERA plus chemotherapy, with and without TEVIMBRA, in first-line HER2-positive advanced or metastatic gastroesophageal adenocarcinoma. Other analyses address lung, gastric and esophageal cancers. No numerical clinical results are disclosed in this announcement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.30%
Tags
none
-
Rhea-AI Summary

BeOne Medicines (NASDAQ: ONC) announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, featuring a fireside chat at 11:30 a.m. EDT. A live and archived webcast will be available in the investors section of the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
Rhea-AI Summary

BeOne Medicines (Nasdaq: ONC) announced a voluntary agreement with the U.S. government to expand American patients’ access to its innovative cancer medicines and strengthen its U.S. manufacturing base. The agreement includes participation in the GENEROUS Model and a commitment to price future FDA-approved products in line with other key developed markets.

According to BeOne, the company secured an exemption from Section 232 pharmaceutical tariffs through an onshoring agreement, supported by a recently announced $300 million investment in its Hopewell, NJ facility, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will add small-molecule capacity and about 120 full-time jobs, supporting a pipeline of over 35 clinical- and commercial-stage assets and 93 clinical trials at around 1,100 U.S. sites.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
none

FAQ

What is the current stock price of BeOne Medicines (ONC)?

BeOne Medicines (ONC) last closed at $411.29.

What is the market cap of BeOne Medicines (ONC)?

The market cap of BeOne Medicines (ONC) is approximately $47.0B.